Amsterdam, the Netherlands — August 26, 2025 — Leads & Copy — Scenic Biotech and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have entered into a license and research agreement. The collaboration will leverage Scenic’s Cell-Seq platform to discover novel targets for RNAi therapeutics.
Scenic Biotech’s Senior Director of Discovery Sciences, Vincent Blomen, PhD, noted the collaboration validates Cell-Seq’s ability to connect cellular pathways to actionable drug targets. Scenic is focused on advancing its pipeline of disease-modifying therapies and empowering partners in developing innovative medicines.
This marks Scenic’s third Cell-Seq collaboration with major US biotech and pharmaceutical companies, including ongoing agreements with Genentech and Bristol Myers Squibb. The Cell-Seq platform delivers genetic insights for therapeutic discovery and development and can map unexplored biological pathways and investigate disease mechanisms.
Scenic Biotech is advancing modifier therapy, a new approach to treating genetic disorders by rebalancing health through action on genes that can improve or bypass disease impact. Scenic’s pipeline, derived from its Cell-Seq platform, includes wholly owned small molecule programs. The platform is also leveraged through strategic collaborations.
Contact:
Scenic Biotech
Oscar Izeboud, PhD, CEO
Phone: +31 20 7059 990
Email: info@scenicbiotech.com
Trophic Communications
Eva Mulder & Desmond James
Phone: +31 65 2331 579
Email: scenic@trophic.eu
Source: Scenic Biotech
